Table 2.
Demographic and clinical characteristics of the sJIA patient plasma samples indicating the gender, ethnicity, age in years at disease onset and at time of collection, presence of joint damage evaluated radiographically and treatment at time of collection
| Sample | Gender | Ethnicity | Age at disease onset (years) | Age at sample collection (years) | Joint damage | Treatment at time of sample collection |
|---|---|---|---|---|---|---|
| 2L | M | Hispanic/White | 8.8 | 17.6 | Yes | Anti-TNF (Etanercept) |
| 5G | M | Hispanic/White | 12.2 | 16.3 | Yes | NSAID, MTX, Anti-TNF (Etanercept) |
| 10 N | F | Asian | 2.7 | 7.9 | Yes | NSAID, Anti-TNF(Etanercept) |
| 14G | M | White | 3.2 | 8.9 | Yes | NSAID, MTX, Anti-TNF(Etanercept), prednisone 1.03mg/kg/day |
| 21J | F | Hispanic/White | 1.7 | 9.5 | Yes | NSAID, MTX, Anti-TNF(Etanercept), prednisone 0.42mg/kg/day |
| 123M | M | White | 11.8 | 15.9 | No | None |